Preventive VT Substrate Ablation in Ischemic Heart Disease

Launched by CENTRO MEDICO TEKNON · Dec 14, 2020

Keywords

ClinConnect Summary

This clinical trial is examining a treatment called preventive VT substrate ablation for patients who have ischemic heart disease, which is a condition where the heart doesn’t get enough blood due to narrowed arteries. The researchers believe that this procedure can help prevent serious heart rhythm problems, known as ventricular tachycardia (VT), in patients who are at high risk. They are looking for participants who are over 18 years old, have stable ischemic heart disease, and have certain heart imaging results showing scar tissue in the heart.

If you or a family member are interested in participating, you would need to meet specific criteria, such as having a life expectancy of more than a year and being in generally good health. Participants will undergo the procedure and will be closely monitored to see how well it works in preventing heart rhythm issues. It’s important to know that individuals who are pregnant, under 18, or who have certain other heart conditions may not be eligible. This trial is currently recruiting participants, and those who join will be helping researchers learn more about this potentially helpful treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \> 18 years.
• • Chronic, stable ischemic heart disease, irrespectively of the LVEF.
• • Life expectancy of \> 1 year with a good functional status.
• • Documented scar AND a BZC mass \> 5.15 g as measured per LGE-CMR and automatic post-processing using the ADAS-3D LV (ADAS 3D Medical SL, Barcelona, Spain).
• • Signed informed consent.
• Exclusion Criteria:
• • Age \< 18 years.
• • Pregnancy.
• • Life expectancy of \< 1 year, or bad functional status (NYHA IV functional class).
• • Other concomitant structural heart diseases (e.g. congenital, non-ischemic, etc.)
• • Previously documented sustained ventricular arrhythmias.
• • Impossibility to perform a contrast-enhanced CMR study.
• • Calculated BZC mass in the scarred tissue \< 5.15 g using the ADAS-3D LV software.
• • Concomitant investigation treatments.
• • Medical, geographical and social factors that make study participation impractical, and inability to give written informed consent. Patient's refusal to participate in the study.